
DexCom DXCM
$ 67.65
0.12%
Quarterly report 2025-Q2
added 07-30-2025
DexCom Gross Profit 2011-2025 | DXCM
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit DexCom
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.29 B | 1.88 B | 1.68 B | 1.28 B | 932 M | 664 M | 492 M | 378 M | 278 M | 176 M | 100 M | 46.6 M | 35.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.29 B | 35.8 M | 787 M |
Quarterly Gross Profit DexCom
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 689 M | 589 M | - | 594 M | 627 M | 562 M | - | 623 M | 546 M | 463 M | - | 494 M | 450 M | 398 M | - | 447 M | 417 M | 344 M | - | 340 M | 284 M | 256 M | 309 M | 247 M | 206 M | 169 M | 223 M | 169 M | 154 M | 119 M | 154 M | 127 M | 118 M | 94.1 M | 117 M | 101 M | 85.5 M | 75.1 M | 91.2 M | 74.7 M | 66 M | 46.5 M | 59.4 M | 47.2 M | 39.9 M | 29.8 M | 34.1 M | 27.6 M | 21.9 M | 16.5 M | 17.5 M | 8.4 M | 11.2 M | 9.4 M | 10.7 M | 8.2 M | 11.9 M | 5.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 689 M | 5.1 M | 212 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
30.6 M | $ 19.06 | -1.6 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
364 M | $ 20.31 | -5.8 % | $ 221 M | ||
|
Co-Diagnostics
CODX
|
2.63 M | $ 0.23 | -4.17 % | $ 6.75 M | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 39.2 | -0.49 % | $ 1.09 B | ||
|
Danaher Corporation
DHR
|
14.2 B | $ 230.87 | 0.23 % | $ 169 B | ||
|
DarioHealth Corp.
DRIO
|
5.98 M | $ 10.36 | 3.19 % | $ 294 M | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.51 | -0.9 % | $ 1.92 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
Exact Sciences Corporation
EXAS
|
493 M | $ 101.86 | 0.28 % | $ 18.9 B | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
107 M | $ 26.63 | -0.34 % | $ 805 M | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 19.19 | -1.49 % | $ 1.03 B | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
Anixa Biosciences
ANIX
|
83.8 K | $ 3.19 | -0.31 % | $ 102 K | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
3.79 B | $ 227.26 | 0.15 % | $ 41.2 B | ||
|
Guardant Health
GH
|
144 M | $ 100.93 | -1.99 % | $ 12.4 B | ||
|
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | ||
|
Myriad Genetics
MYGN
|
585 M | $ 6.32 | -2.55 % | $ 573 M | ||
|
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.75 | -4.81 % | $ 2.55 M | ||
|
Neogen Corporation
NEOG
|
421 M | $ 7.2 | 0.98 % | $ 1.56 B | ||
|
National Research Corporation
NRC
|
81.5 M | $ 18.95 | 1.55 % | $ 465 M | ||
|
Illumina
ILMN
|
2.86 B | $ 134.56 | -0.29 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 203.33 | -0.11 % | $ 10.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 175.36 | -0.34 % | $ 19.5 B | ||
|
Biodesix
BDSX
|
18.5 M | $ 6.79 | -0.44 % | $ 880 M | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Koninklijke Philips N.V.
PHG
|
7.77 B | $ 27.26 | 0.57 % | $ 20 B | ||
|
Laboratory Corporation of America Holdings
LH
|
3.62 B | $ 252.95 | -0.4 % | $ 21.2 B | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 182.75 | -0.05 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
2.38 B | $ 685.99 | -0.36 % | $ 56.6 B | ||
|
Lantheus Holdings
LNTH
|
988 M | $ 67.0 | 0.43 % | $ 4.64 B | ||
|
Personalis
PSNL
|
22.1 M | $ 8.01 | -1.6 % | $ 475 M | ||
|
Mettler-Toledo International
MTD
|
2.33 B | $ 1 419.41 | -0.06 % | $ 30.1 B | ||
|
Agilent Technologies
A
|
2.84 B | $ 138.09 | -0.22 % | $ 42 B | ||
|
Quidel Corporation
QDEL
|
1.35 B | $ 29.27 | -0.12 % | $ 1.23 B | ||
|
Biomerica
BMRA
|
498 K | $ 2.6 | -3.7 % | $ 5.97 M |